Related Experiment Video
Updated: Feb 3, 2026

Visualization of Pseudomonas aeruginosa within the Sputum of Cystic Fibrosis Patients
Published on: July 16, 2020
Potentiators and Correctors in Paediatric Cystic Fibrosis Patients: A Narrative Review
R Dobra1, C Edmondson1, D Hughes1
1The Department of Cystic Fibrosis and Chronic Lung Infection, National Heart and Lung Institute, Imperial College London, Emmanuel Kaye Building, 1B Manresa Road, London, SW36LR, UK.
Insights
New cystic fibrosis treatments target the defective CFTR protein, showing promise in clinical trials. Research is expanding to include younger patients and common mutations, despite high drug costs.
Area of Science:
- Medical Research
- Genetics
- Pharmacology
Background:
- Cystic fibrosis (CF) is a common inherited disorder in Caucasians, significantly reducing life expectancy.
- Current treatment advances focus on correcting the underlying defect in the cystic fibrosis transmembrane conductance regulator (CFTR) protein.
Purpose of the Study:
- To review recent advances in CFTR-targeted therapies for cystic fibrosis.
- To summarize ongoing clinical trials exploring new and existing therapies.
Main Methods:
- Review of clinical trial data for CFTR modulators.
- Analysis of emerging drug pipelines for cystic fibrosis treatment.
- Examination of therapeutic strategies for early-life intervention.
Main Results:
- Several CFTR-targeting drugs have shown promising results and are in clinical use.
- Ongoing trials are evaluating safety and efficacy in pediatric populations.
- Development is progressing for therapies addressing common CFTR mutations.
Conclusions:
- Disease-modifying therapies offer significant potential for improving cystic fibrosis outcomes.
- Early intervention with novel therapies is becoming increasingly relevant.
- High drug costs present a significant challenge for widespread access to these advanced treatments.
Abstract:
Cystic fibrosis is the most common inherited condition in the Caucasian population and is associated with significantly reduced life expectancy. Recent advances in treatment have focussed on addressing the underlying cause of the condition, the defective production, expression and function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Several drugs with different modes of action have produced promising results in clinical trials, and some have been incorporated into routine clinical care for specific patients in many countries worldwide. Further trials continue to explore the safety and efficacy of these drugs in the youngest age groups and to search for more effective therapies to treat the most common disease-causing gene mutations in an ever-expanding drug pipeline. As evidence mounts for the early onset of disease in young patients, the prospect of introducing disease-modifying therapy in early life becomes more pertinent, although the cost implications of these expensive drugs are significant. In this review, we summarise these new therapy advances and review those currently being explored in clinical trials.
More Related Videos
Related Concept Videos
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Cystic Fibrosis: Management
Sinus disease and chronic...
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview
Potential Energy
Chemical bonds that form attractive forces between atoms also contain potential energy, called chemical energy. When a chemical reaction...
Potential Energy

